RIGEL PHARMACEUTICALS INC

Securities Trading Plans of Directors and Executive Officers

During the three months ended June 30, 2026, no directors or executive officers adopted orterminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended.

Credit and Security Agreement

As previously disclosed in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, on May 5, 2026, the Company entered into a Credit and Security Agreement with MidCap Financial Trust providing for a revolving credit facility with an initial maximum borrowing capacity of $40.0 million, with an option to increase the facility to $60.0 million, subject to customary conditions, and simultaneously terminated its prior term loan credit facility. Availability under the revolving credit facility is subject to a borrowing base based primarily on eligible accounts receivable and inventory. The revolving credit facility has a five-year term and bears interest at a rate equal to one-month SOFR, subject to a 2.00% floor, plus an applicable margin of 4.00%. The obligations under the revolving credit facility are secured by a first-priority security interest in substantially all of the Company's assets, including our intellectual property. The revolving credit facility includes customary fees, including an unused commitment fee, administrative fee and prepayment premiums during the initial period. The revolving credit facility contains customary covenants that, among other things, require the Company to deliver financial reports at specified times and maintain minimum liquidity and trailing twelve month product revenue. The minimum product revenue covenant is tested only during periods when the liquidity falls below specified thresholds. All unpaid principal and accrued interest is due and payable in full no later than May 31, 2031. The Company made an initial draw of $8.0 million on May 5, 2026 and an additional draw of $32.0 million on June 29, 2026. The foregoing description of the Credit and Security Agreement is not intended to be complete and is qualified in its entirety by reference to the Credit and Security Agreement, a copy of which is filed as Exhibit 10.4 to this quarterly report on Form 10-Q.